Mereo BioPharma (MREO) Assets Average (2018 - 2026)

Mereo BioPharma (MREO) has 5 years of Assets Average data on file, last reported at $43.3 million in Q1 2026.

• Assets Average for Q1 2026 came in at $43.3 million, down 40.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.3 million (down 40.2% YoY), and the FY2025 annual result was $61.2 million, down 14.4% from the prior year.
• Assets Average eased to $43.3 million in Q1 2026 per MREO's latest filing, from $49.8 million in the prior quarter.
• Over five years, Assets Average peaked at $412.4 million in Q1 2023 and troughed at $43.3 million in Q1 2026.
• A 4-year average of $123.3 million and a median of $76.0 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2025: Assets Average plunged 85.16% in 2024, then increased 18.19% in 2025.
• A 4-year view of Assets Average shows it stood at $84.9 million in 2023, then slipped by 2.75% to $82.6 million in 2024, then slumped by 39.74% to $49.8 million in 2025, then retreated by 13.05% to $43.3 million in 2026.
• Business Quant data shows MREO's Assets Average at $43.3 million in Q1 2026, $49.8 million in Q4 2025, and $58.1 million in Q3 2025.